QCI Asset Management Inc. NY lowered its stake in Johnson & Johnson (NYSE:JNJ) by 3.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 135,910 shares of the company’s stock after selling 5,360 shares during the period. Johnson & Johnson accounts for approximately 2.0% of QCI Asset Management Inc. NY’s holdings, making the stock its 4th largest holding. QCI Asset Management Inc. NY’s holdings in Johnson & Johnson were worth $17,670,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Howe & Rusling Inc. grew its position in Johnson & Johnson by 2.6% in the second quarter. Howe & Rusling Inc. now owns 85,201 shares of the company’s stock worth $11,271,000 after acquiring an additional 2,146 shares in the last quarter. Franklin Street Advisors Inc. NC grew its position in Johnson & Johnson by 2.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 81,212 shares of the company’s stock worth $10,744,000 after acquiring an additional 1,597 shares in the last quarter. St. Johns Investment Management Company LLC grew its position in Johnson & Johnson by 1.3% in the second quarter. St. Johns Investment Management Company LLC now owns 16,283 shares of the company’s stock worth $2,154,000 after acquiring an additional 204 shares in the last quarter. Gemmer Asset Management LLC grew its position in Johnson & Johnson by 42.6% in the second quarter. Gemmer Asset Management LLC now owns 10,246 shares of the company’s stock worth $1,355,000 after acquiring an additional 3,060 shares in the last quarter. Finally, Mascoma Wealth Management LLC grew its position in Johnson & Johnson by 1.5% in the second quarter. Mascoma Wealth Management LLC now owns 7,642 shares of the company’s stock worth $1,011,000 after acquiring an additional 111 shares in the last quarter. Institutional investors own 65.70% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $126.36 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12 month low of $113.40 and a 12 month high of $148.32. The firm has a market cap of $353,062.47, a P/E ratio of 18.00, a PEG ratio of 2.37 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The firm had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same quarter in the previous year, the firm posted $1.58 earnings per share. The company’s revenue was up 11.5% on a year-over-year basis. sell-side analysts expect that Johnson & Johnson will post 8.08 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.66%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 861.54%.

Several research analysts recently commented on JNJ shares. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 price target for the company. in a research report on Friday, October 13th. Leerink Swann restated an “outperform” rating and set a $165.00 target price (up previously from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Royal Bank of Canada boosted their target price on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, October 18th. Stifel Nicolaus boosted their target price on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Finally, BMO Capital Markets restated a “positive” rating and set a $152.00 target price (up previously from $145.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $146.16.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/02/09/johnson-johnson-jnj-stake-decreased-by-qci-asset-management-inc-ny.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.